Clinical Trials
4 trialsNCT03983954 2025-11-28
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
Phase 1 Active not recruiting
NCT05894447 2024-04-12
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Weill Medical College of Cornell University
Phase 1 Withdrawn
NCT00420888 2015-07-22
ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
Active Biotech AB
Phase 2/3 Completed
NCT00056537 2014-08-27
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
Active Biotech AB
Phase 1 Completed